Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole

Biochemical Pharmacology

Volumn 92, Issue 3, 2014, Pages 457-466

  Martínez, Carmen ^a   Andreu, Inmaculada ^b   Amo, Gemma ^a   Miranda, Miguel A ^c   Esguevillas, Gara ^a   Torres, María José ^d   Blanca López, Natalia ^e   Blanca, Miguel ^d   García Martín, Elena ^a   Agúndez, José A G ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

Biomarkers; Metabolism; Metamizole; Polymorphisms

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DIPYRONE; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; NAT2 PROTEIN, HUMAN;

ACETYLATION; ADULT; ALLELE; ARTICLE; DRUG METABOLISM; FEMALE; FORMYLATION; GENDER; GENE DOSAGE; GENETIC ASSOCIATION; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; PROTEIN POLYMORPHISM; SINGLE DRUG DOSE; URINALYSIS; DRUG INACTIVATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; URINE; YOUNG ADULT;

ACETYLATION; ADULT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; DIPYRONE; FEMALE; HUMANS; INACTIVATION, METABOLIC; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84910658689     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.09.005     Document Type: Article

References (48)

1. Basak GW, Drozd-Sokolowska J, Wiktor-Jedrzejczak W. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland. The Journal of International Medical Research 2010;38:1374-80.
2. Wessel JC, Matyja M, Neugebauer M, Kiefer H, Daldrup T, Tarbah FA, et al. Characterization of oxalic acid derivatives as new metabolites of metamizol (dipyrone) in incubated hen's egg and human. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2006;28:15-25.
3. Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2007;21:2343-51.
4. Maj S, Centkowski P. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2004;10:PI93-5.
5. Ibanez L, Vidal X, Ballarin E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 2005;60:821-9.
6. Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2009;39:1217-24.
7. Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2011;41:86-95.
8. Damm D. Simultaneous determination of the main metabolites of dipyrone by high-pressure liquid chromatography. Arzneimittelforschung 1989;39:1415-7.
9. Zylber-Katz E, Granit L, Levy M. Formation and excretion of dipyrone metabolites in man. Eur J Clin Pharmacol 1992;42:187-91.
10. Agundez JA, Carrillo JA, Martinez C, Benitez J. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine. Ther Drug Monit 1995;17:1-5.
11. Levy M, Flusser D, Zylber-Katz E, Granit L. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol 1984;27:453-8.
12. Zanrosso CW, Emerenciano M, Goncalves BA, Faro A, Koifman S, Pombode-Oliveira MS. N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy. Cancer Epidemiology Biomarkers & Prevention 2010;19:3037-43.
13. Agundez JAG, Benitez J. Determination of aminopyrine and dipyrone metabolites in urine. Ther Drug Monit 1996;18:104-7.
14. Agundez JAG, Martinez C, Martin R, Benitez J. Determination of aminopyrine, dipyrone and its metabolites in urine by high-performance liquid-chromatography. Ther Drug Monit 1994;16:316-22.
15. Cohen O, Zylber-Katz E, Caraco Y, Granit L, Levy M. Cerebrospinal fluid and plasma concentrations of dipyrone metabolites after a single oral dose of dipyrone. Eur J Clin Pharmacol 1998;54:549-53.
16. Flusser D, Zylber-Katz E, Granit L, Levy M. Influence of food on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol 1988;34:105-7.
17. Jung S, Tsukuda Y, Kawashima R, Ishiki T, Matsumoto T, Nakaniwa A, et al. Convenient synthesis of acetaminophen analogues containing α-amino acids and fatty acids via their mixed carbonic carboxylic anhydrides in aqueous organic solvent. Tetrahedron Lett 2013;54:5718-20.
18. Linnet K. Evaluation of regression procedures for methods comparison studies. Clin Chem 1993;39:424-32.
19. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 2013;138:103-41.
20. Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K. Improvements in algorithms for phenotype inference: The NAT2 example. Curr Drug Metab 2014;15(2):233-49.
21. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. The American Journal of Human Genetics 2003;73:1162-9.
22. Agundez JAG, Golka K, Martinez C, Selinski S, Blaszkewicz M, Garcia-Martin E. Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008;54:1390-4.
23. Asmardi G, Jamali F. High-performance liquid chromatography of dipyrone and its active metabolite in biological fluids. J Chromatogr 1983;277:183-9.
24. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008;40:623-30.
25. Asmardi G, Jamali F. Pharmacokinetics of dipyrone in man: role of the administration route. Eur J Drug Metab Pharmacokinet 1985;10:121-5.
26. Agundez JA, Martinez C, Benitez J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995;25:417-27.
27. Blanco G, Martinez C, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics and Genomics 2008;18:37-43.
28. Martinez C, Garcia-Martin E, Ladero JM, Sastre J, Garcia-Gamito F, Diaz-Rubio M, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 2001;22:1323-6.
29. Alonso-Navarro H, Martinez C, Garcia-Martin E, Benito-Leon J, Garcia-Ferrer I, Vazquez-Torres P, et al. CYP2C19 polymorphism and risk for essential tremor. Eur J Neurol 2006;13:73.
30. Agundez JA, Abad-Santos F, Aldea A, Alonso-Navarro H, Bernal ML, Borobia AM, et al. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics 2012;3:273.
31. Cabaleiro T, Roman M, Ochoa D, Talegon M, Prieto-Perez R, Wojnicz A, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metabolism and Disposition 2013;41:224-9.
32. Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH, et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorganic & Medicinal Chemistry 2012;20:101-7.
33. Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995;28:216-34.
34. Levy M, Safadi R, Zylber-Katz E, Granit L, Caraco Y. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators. Eur J Clin Pharmacol 2001;57:461-5.
35. Niwa T, Sato R, Yabusaki Y, Ishibashi F, Katagiri M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 1999;29:187-93.
36. Abdalla SO, Elouzi AA, Saad SE, Alem MD, Nagaah TA. Study on the relationship between genetic polymorphisms of cytochrome CYP2C19 and metabolic bioactivation of dipyrone. Journal of Chemical and Pharmaceutical Research 2014;6:992-9.
37. Ruiz JD, Martinez C, Anderson K, Gross M, Lang NP, Garcia-Martin E, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PloS ONE 2012;7:e44629.
38. Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Frias A, et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 2013;28:323-8.
39. Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, et al. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Molecular Diagnosis & Therapy 2012;16:241-50.
40. Levy M, Muszkat M, Rich B, Rosenkranz B, Schlattmann P. Population pharmacokinetic analysis of the active product of dipyrone. Int J Clin Pharmacol Ther 2010;48:791-7.
41. Olsen H, Morland J. Ethanol-induced increase in drug acetylation in man and isolated rat liver cells. Br Med J 1978;2:1260-2.
42. Gupta RC, Nair CR, Jindal SK, Malik SK. Incidence of isoniazid acetylation phenotypes in North Indians. International Journal of Clinical Pharmacology Therapy and Toxicology 1984;22:259-64.
43. Vas A, Gachalyi B, Kaldor A. Pantothenic acid, acute ethanol consumption and sulphadimidine acetylation. International Journal of Clinical Pharmacology Therapy and Toxicology 1990;28:111-4.
44. Olsen H, Morland J. Ethanol interaction with drug acetylation in vivo and in vitro. Pharmacology Biochemistry and Behavior 1983;18(Suppl 1):295-300.
45. Pontes ZB, Vincent-Viry M, Gueguen R, Galteau MM, Siest G. Acetylation phenotypes and biological variation in a French Caucasian population. European Journal of Clinical Chemistry and Clinical Biochemistry: Journal of the Forum of European Clinical Chemistry Societies 1993;31:59-68.
46. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19∗17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metabolism and Disposition 2010;38:894-7.
47. Gomez MJ, Sirtori C, Mezcua M, Fernandez-Alba AR, Aguera A. Photodegradation study of three dipyrone metabolites in various water systems: identification and toxicity of their photodegradation products. Water Res 2008;42:2698-706.
48. Ruiz JD, Martinez C, Anderson K, Gross M, Lang NP, Garcia-Martin E, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS ONE 2012;7(9):e44629. http://dx.doi.org/10.1371/journal.pone.0044629 [Epub 2012 Sep 6].